A first-in-human Phase 1 study of GBR 1342 in patients with multiple myeloma

Trial Profile

A first-in-human Phase 1 study of GBR 1342 in patients with multiple myeloma

Planning
Phase of Trial: Phase I

Latest Information Update: 23 May 2017

At a glance

  • Drugs GBR 1342 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 23 May 2017 New trial record
    • 15 May 2017 According to a Glenmark Pharmaceuticals media release, the US FDA has cleared the company's IND application to initiate a phase I study of GBR 1342.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top